I

n an age with few vaccine makers and still fewer vaccines for many dangerous diseases, a new report card finds that the most important manufacturers are, by and large, doing a mixed job of making their products available to the neediest countries.

Of the six vaccine makers that were evaluated, only GlaxoSmithKline was notable for its efforts in the three categories that were measured: developing new products, making its vaccines affordable, and ensuring that production meets demand, according to the latest Access to Vaccines Index.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.